Innovates technology in treatment of diabetes mellitus

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the present review pancreatic diabetes control methods (pancreatic diabetes treatment peculiarities and glycemia control) are considered on a modern stage. In the scope of the present review mostly control methods for insulin-dependent diabetes are presented as there is very active introduction of new treatment ways in this field is carried out. At the present moment researches are going in several ways: improvement of insulin preparations, development of new methods of the insulin introduction, recovery of b-cells. Further improvement of the glycemia control methods is the most important problem in the diabetology. A particular interest might have a new group ofsugar-decreasing preparations-incritine. mimetic-which might become the base for pathogenesis treatment of the type 2 PD. Review of innovative technologies in pancreatic diabetes treatment already implemented in clinical practice or use of which is very perspective by the authors'opinions is presented in this article.

About the authors

V. I. Mazurov

State Medical Academy of Postgraduate Education

Author for correspondence.
Email: shabanov@mail.rcom.ru

член-корреспондент РАМН

Russian Federation, St. Petersburg

N. V. Vorokhobina

State Medical Academy of Postgraduate Education

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

А. V. Kuznetsova

State Medical Academy of Postgraduate Education

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

N. V. Semenova

State Medical Academy of Postgraduate Education

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

References

  1. Bolli G. В., Capani Е, Kerr D. et al. Comparison of a multiple daily injection regimen with once-daily insulin glarginc basal infusion: a randomized open, parallel study // Diabetologia. 2004. Vol. 837 (Suppl. 1). P.A301.
  2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2003.
  3. DCCT Research Group // N. Engl. J. Med. 1993. Vol. 329. P. 977-986.
  4. DCCT Research Group. The absence of glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial // Diabetes. 1996. № 45. P. 1289-1298.
  5. Deacon С. E, Johnsen A. H., Holst J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo // J. Clin. Endocrinol. Metab. 1995. Vol. 80. P. 952-957.
  6. Deacon С. E, Nauck M. A., Toft-Nielsen M. et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and healthy subjects//Diabetes. 1995. Vol. 44. P. 1126-1131.
  7. Degn К В., Brock В., Juhl С. B. et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and couterregulation during hypoglycemia // Diabetes. 2004. Vol. 53 (9). P. 2397-2403.
  8. Dreyer M., Pein M., Schmidt B. et al. Comparison of the pharmacokinetics/dynamics of GLY(A21)- ARG(B31, B32)-humans insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycemic clamp technique // Diabetologia. 1994. Vol. 37 (Suppl.). P.A78.
  9. Dипп С., P/osker G., Keating G. et al. lnsulin Glargine. An updated review of its in the management of diabetes mellitus // Drugs. 2003. Vol. 63. № 16. Р. 1743-1778.
  10. Edwardf et al. // Science. 1997. Vol. 276. Р. 1868-1871.
  11. Egan J. М, Clocquet А. R., E/ahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes // J. Clin. Endocrinol. Metab. 2002. Vol. 87 (3). Р. 1282-1290.
  12. Elrick Н., Stimm/er L., Н/аd С. J., Turner D. А. Plasma insulin responses to oral and intravenous glucose administration // J. Clin. Endocrinol. Metab. 1964. Vol. 24. Р. 1076-1082.
  13. Fehse F. С., Тrautmann М. Е., Holst J. J. et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes // J.Clin. Endocrinol. Metab. 2005. Vol. 90. Р. 5991-5997.
  14. Garg S., Rosenstock J., Si/verman В. L. et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectaЫe insulin in patients with type 1 diabetes // DiaЬetologia. 2006. Vol. 49. Р. 891-899.
  15. Garg et al. // Diabetologia. 2006. Vol. 49. Р. 891-899.
  16. Hamilton-Wess/er М., Ader М, Dea М et al. Mechanism of protacted metabolic effects of fatty acid acylated insulin, NN304 in dogs: retention of NN304 Ьу albumin // Diabetologia. 1999. Vol. 42. Р. 1254-1263.
  17. Нermans М Р., Nobe/s F. R., de Leeuw L Insulin lispro (Humalog®), а novel fast-acting insulin analogue for treatment of diabetes mellitus: overview of phannacological а clinical data // Acta Clinica Belgica. 1999. Vol. 54. Р. 233-240.
  18. Ho//ander et al. // Diabetes Care. 2004. Vol. 27. Р. 2356-2362.
  19. Jacobsen L. V., Sogaard В., Riis А. Phannakokinetics and phaпnakodynamics of premixed formulation of soluЫe and protamine-retarded insulin aspart// Eur. J. ofClin. Phaпnacol. 2000. Vol. 56. Р. 399-403.
  20. Keating G. М. Exenatide // Drugs. 2005. Vol. 65 (12). Р. 1681-1692.
  21. Кеппу S. J. et al. NIН PuЬlication № 95-1468. 199 5.
  22. Ko/terman О. G., Buse J. В., Fineman М S. et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes // J. Clin. Endocrinol. Metab. 2003. Vol. 88. Р. 3082-3089.
  23. Lindho/m А. New insulins in the treatment of diaЬetes mellitus // Best Practice & Res. Clin. Gastroenterol. 2002. Vol. 16. № 3. Р. 475-492.
  24. Ма/опе J. К, Yang Н., Woodworth J. R. et al. Humalog Mix 25 offers better mealtime glycaemic control in patients with type l or type 2 diabetes // Diabetes & Metabolism. 2000. Vol. 26. Р. 481-487.
  25. Mclntryre N., Ho/dsworth С. D., Turner D. А. New in¬terpretation of oral glucose tolerance // Lancet. 1964. 11. Р. 20-21.
  26. Nie/sen L. L., Young А. А., Parkers D. G. Pharmacology of exenatide (synthetic exendin-4): а potential therapeutic for improved glycemic control oftype 2 diaЬetes // Regul. Rept. 2004. Vol. 117. Р. 77-88.
  27. Oiknine R., Bernbaum М, Mooradian А. D. А critical apprasial of the role of insulin analogues in the management of diabetes mellitus // Drugs. 2005. Vol. 65. № 3. Р. 325-340.
  28. Quattrin et al. // Diabetes Care. 2004. Vol. 27. Р. 2622-2627.
  29. Rave et аl. // DiabetesCare. 2005. Vol. 28. Р. 2400¬2405.
  30. Rosenstock et al. // Ann. Intem. Med. 2005. Vol. 143. Р. 549-558.
  31. Sky/er et al. // Diabetes Care. 2005. Vol. 28. Р. 1630-1635.
  32. UКPDS 16 // Diabetes. 1995. Vol. 44. Р. 1249-1258.
  33. Vi/sbo/1 Т. // Diabetologia. 2004. Vol. 47. Р. 357-366.
  34. Wi/d S. et al. // Diabetes Care. 2004. Vol. 27. Р. 1047-1053.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2008 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.